Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03297515
Other study ID # TG2017
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 15, 2019
Est. completion date September 22, 2020

Study information

Verified date February 2021
Source Ophthalmos Research and Education Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS.


Description:

Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. By the year 2040, the number of people suffering from AMD is estimated to increase by 50%. Stargardt disease is the most prevalent form of macular dystrophy in children, with an estimated prevalence of 1 in 10000. There is no effective treatment available that stops progression or improves vision in patients with dry AMD or Stargardt disease. Considering the success in animal studies and observational human studies with omega-3 fatty acids supplementation when the blood ratio AA (arachidonic acid)/EPA (eicosapentaenoic acid) is <2, the sponsor hypothesizes that, when the blood ratio of AA/EPA is maintained below 2, the visual acuity in the group with active supplements will improve, in comparison to the control group, in patients with moderate and severe dry AMD and moderate and severe Stargardt.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date September 22, 2020
Est. primary completion date September 22, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Men and women ages from 18 to 85 years old. - Group 1: For moderate dry macular degeneration the BCVA must be between 50 and 70 (ETDRS) at Screening Visit V1. There must be a large drusen >125 µm within 1mm from the centre of the fovea. Geographic atrophy can be present but must be >300 µm away from centre of fovea; - Group 2: For severe dry macular degeneration the BCVA must be between 41 and 49 (ETDRS) at Screening Visit V1. Geographic atrophy can involve the fovea but must be <2500 µm in diameter or any size GA but >200 µm from centre of fovea anywhere; - Group 3: For moderate Stargardt disease the BCVA must be between 50 and 70 (ETDRS) at Screening Visit V1. The geographic area must be <2.0 mm in diameter anywhere; - Group 4: For severe Stargardt disease the BCVA must be between 41 and 49 (ETDRS) at Screening Visit V1. The geographic area must be <2.5 mm in diameter anywhere; - Willingness to take the randomised trial investigational product for 6 months; - Willingness to consent and undergo the examinations/blood testing at the visits; - Be able to swallow large soft gel capsules; - Take other supplements as usual; The EPA and DHA intake must be less than 1200 mg/day. Exclusion Criteria: - Any ocular disease in either eye including: Diabetic retinopathy, Central serous retinopathy, Epiretinal membrane, Optic atrophy, Macular hole or pseudohole, Retinal vein occlusion, Amblyopia; - Previous wet AMD in the study eye; - Any previous ocular surgery, which may influence progression of dry macular degeneration e.g. trabeculectomy, previous refractive surgery, pterygium surgery. Cataract surgery more than 6 months is not an exclusion criterion unless a complication has occurred during surgery; - Any topical medication administered for other diseases such as glaucoma. Artificial tears up to 3/day will be allowed; - Any ocular condition such as allergic conjunctivitis, moderate to severe dry eyes, scleritis, uveitis, keratitis, ocular Herpes Simplex keratitis, ectropion, entropion, ocular surface scaring; - Any systemic conditions such as gastrointestinal disease e.g. irritable bowel syndrome, Crohn's disease, cancer, etc; - Any drugs which could affect the eye administered up to 6 months before screening e.g.: Steroids, Ethambutol, Tamoxifen, Chloroquine, Hydroxychloroquine; - Any condition that would not allow follow up e.g. alcoholism or drug abuse; - Allergy to any ingredients of the active or placebo pills. - Pregnant or lactating; - Current use of EPA/DHA supplements in excess of 1200 mg/day; - History of liver disease; - Anti-coagulation therapy such as warfarin/heparin/aspirin/dabigatran/ clopidogrel etc; - Bleeding tendencies e.g. coagulopathies; - History of atrial fibrillation; - Inability to give informed consent (impaired mental capacity e.g. psychiatric deficit); - Smokers or patients who have not been completely smoke free over the past 5 years.

Study Design


Intervention

Dietary Supplement:
Madeos
Arm 1: Omega 3
Placebo
Arm 2 : Placebo

Locations

Country Name City State
France Centre National d'Ophtalmologie des Quinze-Vingts Paris
Germany Department of Ophthalmology, Justus-Liebig-University-Giessen Gießen
Italy Università degli Studi G. d'Annunzio Chieti-Pescara Chieti
Italy ASST Santi Paolo e Carlo Milan
Italy Department of Ophthalmology, University Vita Salute Milan

Sponsors (1)

Lead Sponsor Collaborator
Ophthalmos Research and Education Institute

Countries where clinical trial is conducted

France,  Germany,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change of letters (BCVA) from screening to 24 weeks Mean change of letters (BCVA) from screening to 24 weeks 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04281732 - Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
Recruiting NCT05258032 - Structural and Functional Characterization of Rare Ocular Diseases
Active, not recruiting NCT06300476 - Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1) Phase 1/Phase 2
Recruiting NCT05674058 - Function and Imaging Assessments for G1961E-associated Stargardt Disease
Active, not recruiting NCT05244304 - Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease Phase 3
Recruiting NCT06467344 - Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR) Phase 1/Phase 2
Not yet recruiting NCT06388083 - A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease Phase 2/Phase 3
Recruiting NCT06445322 - Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials
Enrolling by invitation NCT03772938 - Stem Cells Therapy in Degenerative Diseases of the Retina Phase 1